BCM
NKTR icon

Boreal Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Boreal Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51K Hold
36
– – ﹤0.01% 449
2026
Q1 		$2.59K Hold
36
– – ﹤0.01% 439
2025
Q4 		$1.52K Hold
36
– – ﹤0.01% 468
2025
Q3 		$2.05K Hold
36
– – ﹤0.01% 475
2025
Q2 		$930 Buy
+36
New +$404 ﹤0.01% 454

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boreal Capital Management's NKTR Position: Q2 2026 in Review

Boreal Capital Management held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 36 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #449.

Boreal Capital Management first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.59K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Boreal Capital Management held 36 shares of Nektar Therapeutics worth $2.51K as of Q2 2026.
  • Boreal Capital Management left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Boreal Capital Management's portfolio in Q2 2026, its #449 holding.
  • Boreal Capital Management first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Boreal Capital Management's Nektar Therapeutics position peaked at $2.59K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Boreal Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.